Horizon Pharma plc to Participate in BMO Prescriptions for Success Healthcare Conference
30 nov. 2017 16h05 HE
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
30 nov. 2017 06h00 HE
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
Horizon Pharma plc Selected as One of Chicago’s Top Workplaces by the Chicago Tribune
10 nov. 2017 09h30 HE
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07 nov. 2017 16h05 HE
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
Horizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled Gout
06 nov. 2017 12h00 HE
|
Horizon Pharma plc
-- Initial data from investigator-initiated TRIPLE study shows infusion reactions occurred in less than 1 percent of infusions -- -- Analyses further support the efficacy and safety of KRYSTEXXA -- ...
Horizon Pharma plc Announces Third-Quarter and Year-to-Date 2017 Results
06 nov. 2017 07h00 HE
|
Horizon Pharma plc
-- Third-Quarter 2017 Net Sales of $271.6 Million -- -- Third-Quarter 2017 Net Loss of $64.0 Million; Adjusted EBITDA of $108.1 Million -- -- Third-Quarter 2017 GAAP Operating Cash Flow of $68.3...
Horizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age
04 nov. 2017 11h00 HE
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 04, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society of Nephrology Kidney Week 2017
03 nov. 2017 11h00 HE
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 03, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc to Participate in Investor Conferences in November
02 nov. 2017 16h05 HE
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces Availability of PROCYSBI™ (cysteamine bitartrate) in Canada
26 oct. 2017 08h00 HE
|
Horizon Pharma plc
DUBLIN, Ireland, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...